{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 4 of 74', 'Gail Doughton', 'Cambridge Clinical Trials Unit - Cancer Theme', '(Senior Trial Coordinator)', '(CCTU-CT)', 'S4, Box 279,', \"Addenbrooke's Hospital,\", 'Cambridge,', 'CB2 0QQ', 'Telephone: 01223 216674', 'Email: gail.doughton@addenbrookes.nhs.u', 'Claire Mather', 'Cambridge Clinical Trials Unit - Cancer Theme', '(Trial Coordinator)', '(CCTU-CT)', 'S4, Box 279,', \"Addenbrooke's Hospital,\", 'Cambridge,', 'CB2 OQQ', 'Telephone: 01223 348090', 'Email: claire.mather@addenbrookes.nhs.uk', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 5 of 74', 'Table of Contents', '1', 'Protocol Signatures:', '2', '2', 'Trial Contacts', '3', '3 Abbreviations', '7', '4', 'Trial Synopsis', '9', '4.1', 'Trial Flow Chart', '13', '5 Introduction', '14', '5.1', 'Background', '14', '5.2', 'Choice of regimen and intermittent dosing schedule', '15', '6', 'Rationale for the INTERIM Trial', '16', '7', 'Trial Design', '17', '7.1', 'Statement of design', '17', '7.2', 'Number of Centres', '17', '7.3', 'Number of Patients', '17', '7.4', 'Patients Trial duration', '17', '7.5', 'Trial objectives', '17', '7.6', 'Trial Enpoints', '18', '8', 'Selection and withdrawal of patients', '19', '8.1', 'Inclusion Criteria', '19', '8.2', 'Exclusion Criteria', '20', '8.3', 'Patient consent', '20', '8.4', 'Screening Procedures and Pre-randomisation investigations', '20', '8.5', 'Treatment Assignment and Randomisation Number', '22', '8.6', 'Patient withdrawal criteria', '22', '9', 'Trial Treatments', '23', '9.1', 'General Principles', '23', '9.2', 'Investigational Medicinal products', '23', '9.3', 'Treatment Summary', '24', '9.4', 'Drug storage, supply and accountability', '25', '9.5', 'Known drug reactions & interaction with other therapies', '26', '9.6', 'Dosage modifications', '26', '9.7', 'Additional treatment', '28', '9.8', 'Treatment for Disease Progression', '29', '9.9', 'Co-enrolment guidelines', '29', '10', 'Procedures and assessments', '29', '10.1 Screening evaluation, pre-randomisation and randomisation procedures', '30', '10.2', 'Trial assessments', '30', '10.3', 'Disease Progression', '32', '10.4', 'Follow-up if stopping treatment prior to disease progression', '32', '10.5', 'Follow-up if stopping treatment at or beyond disease progression', '33', '10.6', 'End of Trial Participation', '33', '10.7', 'Schedule of Assessments', '34', '10.8', 'Trial restrictions', '36', '11', 'Assessment of Safety', '36', '11.1', 'Definitions', '36', '11.2', 'Expected Adverse Reactions/Serious Adverse Reactions (AR', '37', '11.3', 'Expected Adverse Events/Serious Adverse Events (AE/SAE)', '38', '11.4', 'Evaluation of adverse events', '38', '11.5', 'Reporting serious adverse events', '39', '11.6 Reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs)', '40', '11.7', 'Pregnancy Reporting', '41', '12', 'Evaluation of Patient Reported Outcome, Health Economics & Patient', 'Experience Assessments', '41', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 6 of 74', '12.1 Patient Reported Outcome (PRO)', '42', '12.2', 'Health Economics assessments', '43', '12.3', 'Patient Experience evaluation', '43', '13', 'Research Blood and Tissue Samples', '44', '13.1', 'Translational Research', '44', '13.2', 'Pharmacokinetics', '45', '14', 'Statistics', '45', '14.1', 'Number of Patients to be enrolled', '45', '14.2', 'Statistical analysis methods', '46', '14.3', 'Interim analyses', '48', '14.4', 'Definition of the end of the trial', '48', '15', 'Data handling and record keeping', '48', '15.1', 'Case Report Form (CRF)', '48', '15.2', 'Source Data', '49', '15.3 Data Protection & Patient Confidentiality', '49', '16', 'Trial Committees', '49', '16.1 Trial management Group (TMG)', '49', '16.2', 'Independent Safety Data Monitoring Committee (ISDMC)', '49', '16.3', 'Trial Steering Committee (TSC)', '50', '17', 'Ethical & Regulatory considerations', '50', '17.1', 'Consent', '50', '17.2', 'Ethical committee review', '50', '17.3', 'Regulatory Compliance', '50', '17.4', 'Protocol Amendments', '51', '17.5', 'Peer Review', '51', '17.6 Declaration of Helsinki and Good Clinical Practice', '51', '17.7', 'GCP Training', '51', '18', 'Sponsorship, Financial and Insurance', '51', '19', 'Monitoring, Audit & Inspection', '51', '20', 'Protocol Compliance and Breaches of GCP', '52', '21', 'Publications policy', '52', '22', 'References', '53', '23', 'Appendices', '56', '23.1', 'Appendix 1 - RECIST Version 1.1', '56', '23.2 Appendix 2 - Karnofsky and ECOG Performance Status Scale', '60', '23.3', 'Appendix 3 - NYHA Functional Classification', '61', '23.4', 'Appendix 4 - Trial Management / Responsibilities', '62', '23.5', 'Appendix 5 - Authorisation of Participating Sites', '63', '23.6', 'Appendix 6 Sample size ouput and predictive power', '64', '23.7', 'Appendix 7 - Safety reporting flowchart', '66', '23.8', 'Appendix 8 - Reference Safety Information (RSI)', '67', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}